Maccura Biotech extends guarantees, re-invests idle funds for returns

Maccura Biotechnology Co., Ltd. has updated the market on two key financial activities. The company extended credit guarantees for two major distributors, Chengdu Yintai Biotechnology Co., Ltd. and Sichuan Zhenghongkang Medical Instruments Co., Ltd., each for RMB 20 million. These guarantees, approved by the board and shareholders in October 2024, are valid for one year and cover various banking services. The total effective external guarantee limit, including subsidiaries, stands at RMB 1.3 billion, with a utilized balance of RMB 472.07 million.

In related news, Maccura Biotechnology announced the redemption and reinvestment of idle raised funds. The company redeemed a principal of RMB 50 million from a structured deposit with Bank of China Chengdu Shudu Sub-branch, yielding a profit of RMB 225,300. This redemption was part of a larger strategy to manage up to RMB 60 million of idle funds through highly liquid and secure wealth management products.

Following the redemption, Maccura Biotechnology reinvested RMB 50 million into a new structured deposit with Bank of China Chengdu Shudu Sub-branch, maturing on January 13, 2026, with an expected annual yield of 0.55%-1.75%. The company emphasizes that these financial maneuvers do not impact its core business or investment projects, aiming instead to enhance returns for the company and its shareholders.